Alkermes buys into specialty pharma

Alkermes Inc.'s acquisition of Reliant Pharmaceuticals LLC checks two boxes in ALKS's bid to become a big cap specialty pharmaceutical company. The deal puts ALKS within spitting distance of the top tier of biotech companies valued above $3 billion, and, perhaps more importantly, provides the company with the marketing infrastructure to compete for in-licensing drugs.

"There's a major shift to size and scale in this transaction," said CEO Richard Pops. "We go from being one

Read the full 745 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE